Industry & Business

Science Foundation Ireland and Pfizer announce exciting new R&D programme for Ireland

 Breaking News
  • Greencore to Divest US Business in $1 Billion Deal Greencore Group, the Irish and UK convenience food business, has agreed to sell its entire US business to an affiliate of Hearthside Food Solutions for US$1.075 billion (£817 million) on a cash and debt-free basis. Hearthside is a major US contract food manufacturer with a heritage in US food industry outsourcing. The disposal will leave [...]...
  • Research and Innovation Critical to Business Success Post Brexit The Managing Director of the Industry Research and Development Group (IRDG) says increased investment in research and innovation by both the business sector and the State is critical in order for Irish businesses to survive the hard hitting impact of Brexit. Denis Hayes says despite budget 2019 proposals State expenditure on research and innovation will [...]...
  • Irish Distillers to Invest €150 Million in Sites in Cork and Dublin Irish Distillers has announced investment of over €150 million in its sites in Cork and Dublin to meet demand for its products as the Irish whiskey renaissance continues apace. This is accelerated by the continued growth of the company’s flagship Jameson brand, which is now in double or triple-digit growth in more than 80 markets [...]...
  • CM Precision Components Opens New Purpose-built Factory in Downpatrick Downpatrick-based CM Precision Components Ltd has officially opened its new 16,000 sq ft manufacturing facility at Invest Northern Ireland’s Killough Road Industrial Estate. The advanced engineering firm has invested almost £1 million in the construction project, to expand its production capabilities and meet the growing demands of its customers. CM Precision Components produces precision machined components for [...]...
  • Arkphire Secures New Investment IT solutions and networking company, Arkphire, has announced that Bregal Milestone, a private capital firm, has completed an investment into the business. The investment by Bregal Milestone comes from their new €400 million pan-European fund dedicated to investing in high-growth European companies. Typical commitments from Bregal Milestone range from €20 million to €60 million. Arkphire provides [...]...

Science Foundation Ireland and Pfizer announce exciting new R&D programme for Ireland

April 14
08:55 2016

sfi-logoScience Foundation Ireland and Pfizer today announced the recipients of the 2016 SFI-Pfizer Biotherapeutics Innovation Award programme. The collaboration between Science Foundation Ireland and Pfizer provides qualified academic researchers with an opportunity to deliver important potential discoveries in the areas of immunology, oncology, cardiovascular and rare diseases.

Supported by the Department of Jobs, Enterprise and Innovation, the SFI-Pfizer Biotherapeutics Innovation Award programme has awarded funding to researchers from across three academic institutions in Ireland including the Royal College Surgeons (RCSI), University College Cork (UCC) and University College Dublin (UCD).

In addition to the funding, academic researchers will have the unique opportunity to work with the Pfizer Global Biotherapeutics Technology (GBT) group, at Grangecastle in Dublin, as well as Pfizer’s R&D innovation engine, the Centers for Therapeutic Innovation. The teams’ research will focus on the application of cutting edge technologies for next generation protein therapies.

Speaking at the announcement, Mr Damien English, TD, Minister for Research, Skills and Innovation, said: “The collaboration between Science Foundation Ireland and Pfizer is an excellent example of how government, industry and academia can work together and share knowledge that could lead to the development of new medical breakthroughs not only for Irish patients but for patients worldwide. The Government continues to encourage and welcome programmes that offer opportunities in research and development in Ireland. Innovative partnerships and meaningful collaboration between industry and academia like this also help to build Ireland’s reputation internationally as a location for excellent scientific research.”

Commenting at the announcement, Prof Mark Ferguson, Director General of Science Foundation Ireland and Chief Scientific Adviser to the Government of Ireland said, “We are delighted to continue this successful partnership with Pfizer to support innovative research and development that could help deliver significant advances in critical areas of medical need.  The success of the award programme is a reflection of the quality and relevance of academic scientific research in Ireland – excellence and impact.”

Commenting on the announcement, Dr. Paul Duffy, Vice President, Biopharmaceutical Operations and External Supply, Pfizer said, “Pfizer are delighted with the continued collaboration with Science Foundation Ireland. As an organisation we are focused on delivering innovative therapies that significantly improve patients’ lives and investment in early stage research is critical to achieving this. Collaborations between industry and academia remain key in helping to expedite the translation of scientific discoveries into breakthrough therapies that matter for patients in need.”

In 2015, five proposals representing four institutions across Ireland were awarded similar funding. Over the past year the researchers have worked in collaboration with Pfizer colleagues on potential new therapies for diseases including haemophilia, fibrosis, Motor Neuron Disease, psoriasis and Crohn’s disease. A number of these programmes are advancing and are on track to reaching their goals.

The recipients of the SFI-Pfizer Biotherapeutics Innovation Award are:

  • Prof Martin Steinhoff, University College Dublin – Prof Steinhoff leads a translational research team attempting to understand the molecular mechanisms underlying skin inflammation and associated chronic itch, for which there remains a significant unmet clinical need. The team hopes to generate targeting molecules that block the activation of key players in these inflammatory pathways.
  • Dr Anne Moore, University College Cork – The remit of Dr Moore’s group is to develop and translate innovative therapies that modulate immune function. Mounting evidence from recent clinical studies demonstrates that harnessing the body’s own immune response to kill tumour cells can be a very effective mechanism to treat cancer. This collaboration aims to develop a novel strategy that enhances the body’s natural anti-tumour response.
  • Dr Leonie Young and Prof Arnold Hill, Royal College of Surgeons of Ireland – Dr Young and Prof Arnold Hill are interested in the underlying mechanisms that control breast cancer resistance to traditional chemotherapeutics. Their aim is to use pre-clinical models, clinical datasets and breast cancer patient samples to better characterize, and effectively target, treatment resistant breast cancers.

About Author

admin

admin

Related Articles

New Subscriber





Subscribe Here



Advertisements



















National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4